Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume32.00K
Average Volume (3M)106.78K
Market Cap
C$21.19M
Enterprise ValueC$25.07M
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding192,677,950
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationA ~245% revenue jump in 2025 indicates durable top-line momentum and growing market traction for its device offering. Sustained revenue growth can fund R&D and scale fixed costs, improving the odds of eventual operating leverage if growth persists.
Improving Gross MarginGross margin rising to ~66% suggests attractive unit economics and potential pricing/premium positioning. High product-level margins create a structural lever for future profitability when fixed costs and SG&A are controlled, improving long-term viability.
Reduced Operating Cash BurnAn improving operating cash burn rate shows management progress on cost containment or sales mix shift. If sustained, lower cash outflows reduce near-term funding needs and increase runway, making recovery or scaling less dependent on immediate capital raises.
Bears Say
Deep Negative ProfitabilityAn extremely negative net margin and multi-million dollar operating losses indicate the business is not yet near break-even. Persistent losses erode capital, limit reinvestment capacity, and require external financing until sustained operating profitability is achieved.
Stressed Balance SheetDeeply negative equity and rising debt weaken financial flexibility and increase refinancing risk. With limited asset backing (~$0.47M assets in 2025), the company faces constrained options for funding growth or absorbing shocks without dilutive or costly capital.
Persistent Cash Burn And Negative FCFConsistent negative operating cash flow and worsening free cash flow mean losses convert into real cash outflows. This structural cash burn forces reliance on external financing and creates execution risk if capital access tightens or investor support wanes.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$21.19M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 35 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,677,950 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.